Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06889350
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06339788
- Locations
- 🇰🇷
Central Hospital, Siheung-si, Gyeonggi-do, Korea, Republic of
Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05688085
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05688098
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT05663073
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 235
- Registration Number
- NCT05504239
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT05504226
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 271
- Registration Number
- NCT05476354
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- Drug: Irbesartan/Amlodipine
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 157
- Registration Number
- NCT05475665
- Locations
- 🇰🇷
Hanyang University Seoul Hospital, Seoul, Korea, Republic of
A Retrospective Study to Evaluate the Clinical Outcome According to Treatment in aHUS Patients in South Korea
Completed
- Conditions
- aHUS
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT05405777
- Locations
- 🇰🇷
Handok, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath